Azusa Terasaki, Hiroko Bando, Aya Ueda, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Yuzuru Kondo, Hisato Hara
{"title":"Local recurrence of breast cancer histologically resembling Paget disease presumably due to needle tract seeding: a case report.","authors":"Azusa Terasaki, Hiroko Bando, Aya Ueda, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Yuzuru Kondo, Hisato Hara","doi":"10.1007/s13691-023-00594-x","DOIUrl":"10.1007/s13691-023-00594-x","url":null,"abstract":"<p><p>Seeding of cancer cells along the needle tract during core needle biopsy is a well-known phenomenon, with a reported frequency of between 22 and 50% [Hoorntje et al. in Eur J Surg Oncol 30:520-525, 2004;Liebens et al. in Maturitas 62:113-123, 2009;Diaz et al. in AJR Am J Roentgenol 173:1303-1313, 1999;]. Local recurrence due to needle tract seeding is rare because the immune system eliminates the cancer cells in most cases. In addition, most local recurrences due to needle tract seeding occur as invasive carcinoma after diagnosis of invasive ductal carcinoma of the breast or mucinous carcinoma, and needle tract seeding due to noninvasive carcinoma is uncommon. We herein report a rare case of local breast cancer recurrence histologically resembling Paget disease, presumably due to needle tract seeding after core needle biopsy for diagnosis of ductal carcinoma in situ of the breast. After receiving a diagnosis of ductal carcinoma in situ, the patient underwent skin-sparing mastectomy and breast reconstruction with a latissimus dorsi musculocutaneous flap. The pathological study showed ER/PgR-negative ductal carcinoma in situ, and no postoperative radiation therapy or systemic therapy was administered. Six months after the surgery, the patient had a breast cancer recurrence histologically resembling Paget disease, presumably in the scar of her core needle biopsy. The pathological study showed Paget disease localized in the epidermis, no invasive carcinoma, and no lymph node metastasis. It was morphologically similar to the primary lesion and was diagnosed as a local recurrence due to needle tract seeding.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"143-148"},"PeriodicalIF":0.7,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9086356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rhabdomyosarcoma mimicking lymphoma.","authors":"Marziyeh Ghalamkari, Mahdi Khatuni, Haniyeh Radkhah, Saeed Farzanehfar, Behnaz Jahanbin","doi":"10.1007/s13691-023-00595-w","DOIUrl":"10.1007/s13691-023-00595-w","url":null,"abstract":"<p><strong>Background: </strong>Rhabdomyosarcoma (RMS) is a malignant soft tissue tumor that accounts for approximately one-half of soft tissue sarcomas in childhood age groups. Metastatic RMS is a rare condition that occurs in less than 25% of patients at diagnosis and can have variable clinical presentations.</p><p><strong>Case presentation: </strong>Here we report a 17-year-old boy with history of weight loss, fever and generalized bone pain admitted for severe hypercalcemia. The definite diagnosis of RMS was performed with immune-phenotyping of the metastatic lymph-node biopsy. The primary tumor site was not found. His bone scan showed diffuse bone metastasis and significant soft tissue technetium uptake due to extra-osseous calcification.</p><p><strong>Conclusion: </strong>Metastatic RMS can mimic lymphoproliferative disorders at presentation. Clinicians must be aware of this diagnosis especially in young adults.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"149-152"},"PeriodicalIF":0.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Total pancreatectomy preserving the right gastroepiploic artery following proximal gastrectomy.","authors":"Kyohei Yugawa, Naoto Kojo, Shohei Yamaguchi, Shigeyuki Nagata, Takashi Maeda","doi":"10.1007/s13691-023-00596-9","DOIUrl":"10.1007/s13691-023-00596-9","url":null,"abstract":"<p><p>Total pancreatectomy (TP) after proximal gastrectomy (PG) requires more attention than ordinary TP during surgery in terms of the preservation of blood flow to the remnant stomach that was supplied via only the right gastric and gastroepiploic arteries. The current report presents the details of a case in which the remnant stomach was safely preserved when performing TP. A 74-year-old man who underwent PG for gastric cancer 17 years previously was diagnosed with pancreatic head cancer during follow-up for intraductal papillary mucinous neoplasm of the pancreatic body and tail. To preserve digestive function and reduce postoperative complications, TP preserving the right gastroepiploic artery and splenic vessels was performed. The remnant stomach and function were safely preserved without any complications after surgery.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"153-159"},"PeriodicalIF":0.7,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9088045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Misaki Koyama, Ken Yamaguchi, Yoshitsugu Chigusa, Koji Yamanoi, Mana Taki, Masumi Sunada, Akihito Horie, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai
{"title":"<i>ATM</i> mutation in aggressive uterine adenosarcoma in which systemic chemotherapies had remarkable effects.","authors":"Misaki Koyama, Ken Yamaguchi, Yoshitsugu Chigusa, Koji Yamanoi, Mana Taki, Masumi Sunada, Akihito Horie, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai","doi":"10.1007/s13691-022-00591-6","DOIUrl":"10.1007/s13691-022-00591-6","url":null,"abstract":"<p><p>Uterine adenosarcoma is a rare gynecologic malignancy, and 10-25% of the cases exhibit clinically aggressive behaviors. Although <i>TP53</i> mutations are frequently identified in high-grade adenosarcomas of the uterus, definitive gene alterations have not been identified in uterine adenosarcomas. Specifically, no reports have described mutations in homologous recombination deficiency-related genes in uterine adenosarcomas. This study presents a case of uterine adenosarcoma without sarcomatous overgrowth but with <i>TP53</i> mutation that exhibited clinically aggressive behaviors. The patient had an <i>ATM</i> mutation, which is a gene associated with homologous recombination deficiency, and exhibited a good response against platinum-based chemotherapy and possible therapeutic target by poly(ADP-ribose) polymerase inhibitors.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"120-125"},"PeriodicalIF":0.7,"publicationDate":"2023-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case of advanced breast cancer with Gitelman syndrome.","authors":"Yuko Tanaka, Miyuki Muramatsu, Yoshihiro Miyauchi, Yoshio Suzuki, Tamaki Morohashi, Kandai Nozu","doi":"10.1007/s13691-022-00593-4","DOIUrl":"10.1007/s13691-022-00593-4","url":null,"abstract":"<p><p>Gitelman syndrome (GS) is a rare, mostly autosomal recessive disease this is a salt-losing tubulopathy caused by mutation of genes encoding sodium chloride (NCCT) and magnesium transporters in the thiazide-sensitive segments of the distal nephron. We encountered a 45-year-old female who has suffered from whole-body weakness because of hypokalemia for 8 years and diagnosed with Gitelman syndrome clinically. She visited the hospital with a complaint of an unrelieved hard mass of the left breast. The tumor was diagnosed as human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We herein report this first case of a breast cancer patient with Gitelman syndrome who developed other neoplasms including colon polyp, adrenal adenoma, an ovarian cyst, and multiple uterine fibroids and provide a review of the pertinent literature.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"137-142"},"PeriodicalIF":0.7,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto
{"title":"Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with <i>BRCA1</i> mutation: a case report.","authors":"Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto","doi":"10.1007/s13691-022-00592-5","DOIUrl":"10.1007/s13691-022-00592-5","url":null,"abstract":"<p><p>A 67-year-old man with metastatic prostate cancer was treated with leuprorelin and enzalutamide, but presented radiographic progression after 1 year. Although docetaxel chemotherapy was initiated, liver metastasis appeared with elevation of nerve-specific enolase in serum. Pathological findings of needle biopsy of lymph node metastasis in the right inguinal region showed neuroendocrine carcinoma. FoundationOne CDx<sup>®</sup> using a biopsy sample of the prostate at initial diagnosis detected the <i>BRCA1</i> mutation (deletion of intron 3-7), but BRACAnalysis<sup>®</sup> test revealed no <i>BRCA</i> mutation in germline. Then, olaparib treatment was initiated, resulting in remarkable remission of tumors, but comorbidity with interstitial pneumonia. This case suggested that olaparib could be effective for neuroendocrine prostate cancer with <i>BRCA1</i> gene mutation, but may cause interstitial pneumonia.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"131-136"},"PeriodicalIF":0.7,"publicationDate":"2023-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lenvatinib-refractory thymic mucinous carcinoma with <i>PIK3CA</i> mutation.","authors":"Akihiro Tsukaguchi, Shoichi Ihara, Hironao Yasuoka, Seigo Minami","doi":"10.1007/s13691-022-00573-8","DOIUrl":"https://doi.org/10.1007/s13691-022-00573-8","url":null,"abstract":"<p><p>Mucinous adenocarcinoma, a very rare type of thymic carcinoma, is aggressive and has a poor prognosis. The optimal treatment for advanced thymic mucinous adenocarcinoma has not yet been established because of its rarity. An oral multi-tyrosine kinase inhibitor, lenvatinib, was approved for treatment of thymic carcinoma in March 2021 in Japan. However, to the best of our knowledge, there are no published reports concerning lenvatinib for thymic mucinous adenocarcinoma. Herein, we report a 39-year-old woman who presented with a 70 mm multilocular cystic tumor in her left anterior mediastinum and a massive pericardial effusion. We diagnosed a Masaoka stage IVb thymic mucinous adenocarcinoma with multiple metastases to the liver and bones, and pericardial dissemination on the basis of the pathologic findings on examination of a video-assisted thoracoscopic tumor biopsy and radiological examinations. She received paclitaxel-carboplatin-based chemotherapy, but developed a left cerebellar metastasis. Second-line chemotherapy with lenvatinib failed to suppress the tumor. She died of cancer progression 5 months after presentation. Here, we report what we believe to be the first case of a thymic mucinous adenocarcinoma treated with lenvatinib. Our patient's thymic mucinous adenocarcinoma was refractory to both cytotoxic chemotherapy and lenvatinib. Using next-generation sequencing, we identified phosphatidylinositol 3-kinase catalytic subunit alpha mutation in the tumor. We suspected an association between this mutation and resistance to lenvatinib. We therefore recommend performing next-generation sequencing when considering introduction of lenvatinib for thymic mucinous adenocarcinoma. A surgical procedure may be necessary for accurate diagnosis and genetic analysis of this histological tumor type.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"36-40"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807735/pdf/13691_2022_Article_573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10037866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Philippe Westerlinck, Nicolas Janin, Philippe Coucke
{"title":"Rapid-onset paraneoplastic cerebellar degeneration successfully treated by radiotherapy and tumorectomy.","authors":"Philippe Westerlinck, Nicolas Janin, Philippe Coucke","doi":"10.1007/s13691-022-00569-4","DOIUrl":"https://doi.org/10.1007/s13691-022-00569-4","url":null,"abstract":"<p><p>We report the first-ever documented case of successful treatment of paraneoplastic cerebellar degeneration (PCD) with radiotherapy. A 31-year-old female presented with rapidly progressing neurological symptoms, which were revealed to be due to PCD secondary to an undiagnosed breast cancer. The cancer responded well to chemotherapy, but her neurological status continued to deteriorate, eventually progressing to complete expressive aphasia and dyssynergia with paraparesis. Due to the extraordinarily rapid progression of the disorder, a treatment with tumorectomy and radiotherapy of the whole brain was performed. This proved to be very successful, with a complete stop of the deterioration of symptoms after treatment and with a significant neurologic improvement in the following months. This case indicates that there may be a place for radiotherapy in the treatment of PCD. Current treatment options have proven insufficient and no guidelines for treatment currently exist. As such, the disorder remains associated with a very poor prognosis and often entails permanent loss of function. Radiation, with its known immunosuppressive effect and non-stochastic effects on the nervous system at the proper doses, might therefore be a valid option. However, we should note that it was in this instance combined with a removal of the primary tumor and as such, its individual efficacy cannot be considered proven.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"19-23"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807696/pdf/13691_2022_Article_569.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Systemic chemotherapy for unresectable or recurrent primary thymic adenocarcinoma of enteric type.","authors":"Xiaofang Gao","doi":"10.1007/s13691-022-00575-6","DOIUrl":"https://doi.org/10.1007/s13691-022-00575-6","url":null,"abstract":"<p><p>Primary thymic adenocarcinoma of enteric type is a very rare subtype of thymic carcinoma. Choosing appropriate systemic chemotherapy for patients with unresectable or recurrent disease remain a big challenge. We present a case of 38-year-old man with primary thymic adenocarcinoma of enteric type. The patient received multiline chemotherapy. Metastatic lesions were effectively controlled by FOLFOX (oxaliplatin/5-fluorouracil/leucovorin) chemotherapy. According to the present case and the literature review, FOLFOX and XELOX (capecitabine/oxaliplatin) regimens are reasonable treatment choice for unresectable or recurrent primary thymic adenocarcinoma of enteric type, even in the first-line chemotherapy.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"46-48"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807699/pdf/13691_2022_Article_575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10536320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy associated with gastric cancer and response to immediate chemotherapy.","authors":"Kohei Fujita, Takeshi Omori, Hisashi Hara, Naoki Shinno, Masaaki Yamamoto, Takashi Kanemura, Tomohira Takeoka, Takahito Sugase, Hiroshi Miyata, Masayuki Ohue, Masato Sakon","doi":"10.1007/s13691-022-00566-7","DOIUrl":"https://doi.org/10.1007/s13691-022-00566-7","url":null,"abstract":"<p><p>Pulmonary tumor thrombotic microangiopathy is a rare and fatal complication of cancer that features widespread tumor cell-derived embolisms in the small arteries and arterioles of the lung and is often associated with thrombus formation. We describe the case of a 43-year-old woman who was hospitalized with cough and respiratory distress that lasted for 2 months. Computed tomography findings demonstrated multiple areas of interlobular septal thickening and ground-glass opacities in both lungs. Transthoracic echocardiography demonstrated a D-shaped left ventricle suggesting right heart overload, and pulmonary blood flow scintigraphy revealed multiple small, peripheral, and patchy areas of reduced blood flow. Upper gastrointestinal endoscopy revealed a signet-ring carcinoma. The patient was diagnosed with pulmonary tumor thrombotic microangiopathy based on her clinical presentation and treatment with tegafur, gimeracil oteracil potassium, oxaliplatin, and an anticoagulant was initiated on the 3rd day after admission. The symptoms improved rapidly after treatment initiation. The patient was discharged 28 days after initiation of chemotherapy without the need for supplemental oxygen. This case suggests that the immediate use of chemotherapy and anticoagulants for treating pulmonary tumor thrombotic microangiopathy may improve patient survival.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"1-6"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807729/pdf/13691_2022_Article_566.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9890984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}